Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$5.96 +1.0%	$4.40	$3.35 ▼ $20.55	$154.20M	1.01	299,417 shs	262,492 shs
KRRO Korro Bio	$13.85 -7.4%	$13.41	$10.29 ▼ $98.00	$130.06M	2.51	119,372 shs	144,034 shs
MRSN Mersana Therapeutics	$6.60 -3.6%	$8.50	$6.37 ▼ $70.75	$32.90M	0.83	130,548 shs	110,562 shs
NKTX Nkarta	$2.12 -2.3%	$1.87	$1.31 ▼ $6.63	$150.43M	0.72	567,093 shs	472,909 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	0.00%	+3.29%	+49.94%	+45.37%	-70.29%
KRRO Korro Bio	0.00%	-13.49%	+7.36%	-33.83%	-70.25%
MRSN Mersana Therapeutics	0.00%	-18.04%	-8.97%	-33.62%	-86.80%
NKTX Nkarta	0.00%	-1.85%	+20.80%	+1.44%	-67.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	2.4985 of 5 stars	3.6	3.0	0.0	1.1	0.8	1.3
KRRO Korro Bio	1.3282 of 5 stars	3.6	1.0	0.0	0.6	0.0	0.6
MRSN Mersana Therapeutics	3.8551 of 5 stars	3.4	4.0	4.1	0.6	2.5	0.0
NKTX Nkarta	2.3202 of 5 stars	3.6	0.0	0.0	4.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	277.52% Upside
KRRO Korro Bio	3.29	Buy	$102.43	639.56% Upside
MRSN Mersana Therapeutics	2.83	Moderate Buy	$130.00	1,869.70% Upside
NKTX Nkarta	3.13	Buy	$14.33	576.10% Upside

Current Analyst Ratings Breakdown

Latest MRSN, NKTX, KRRO, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$225.00 ➝ $250.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$75.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	3.08	N/A	N/A	$7.66 per share	0.78
KRRO Korro Bio	$2.27M	57.29	N/A	N/A	$17.12 per share	0.81
MRSN Mersana Therapeutics	$40.50M	0.81	N/A	N/A	($1.92) per share	-3.44
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.75	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)

Latest MRSN, NKTX, KRRO, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$5.25	-$4.75	+$0.50	-$0.19	$6.05 million	$2.75 million
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
KRRO Korro Bio	N/A	9.41	9.41
MRSN Mersana Therapeutics	N/A	1.83	1.83
NKTX Nkarta	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
KRRO Korro Bio	13.18%
MRSN Mersana Therapeutics	93.92%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
KRRO Korro Bio	4.60%
MRSN Mersana Therapeutics	13.00%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable

MRSN, NKTX, KRRO, and CTNM Headlines

Recent News About These Companies

Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) PT at $14.33

August 2 at 2:37 AM | americanbankingnews.com

Monaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)

July 31 at 6:50 AM | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

July 30, 2025 | marketbeat.com

Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series

July 23, 2025 | tmcnet.com

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

July 23, 2025 | globenewswire.com

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

July 22, 2025 | seekingalpha.com

Peapod Lane Capital LLC Purchases New Stake in Nkarta, Inc. (NASDAQ:NKTX)

July 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by Brokerages

July 5, 2025 | marketbeat.com

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27, 2025 | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 7, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.comQ

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

William Blair Downgrades Nkarta (NKTX)

May 15, 2025 | msn.com

Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 15, 2025 | finanznachrichten.de

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025 | globenewswire.com

Nkarta (NKTX) Upgraded to Buy: Here's Why

April 14, 2025 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRSN, NKTX, KRRO, and CTNM Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$5.96 +0.06 (+1.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.96 0.00 (0.00%)

As of 08/1/2025 06:33 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Korro Bio NASDAQ:KRRO

$13.85 -1.11 (-7.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.84 -0.01 (-0.07%)

As of 08/1/2025 04:10 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Mersana Therapeutics NASDAQ:MRSN

$6.60 -0.25 (-3.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.60 0.00 (0.00%)

As of 08/1/2025 07:43 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$2.12 -0.05 (-2.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.04 (-2.12%)

As of 08/1/2025 07:45 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time